Polycythemia vera (PV) is the most prominent myeloproliferative neoplasm (MPN), the final phenotypic effect of Janus kinase-2 (JAK2) somatic gene mutations, and the most frequently MPN accompanied by arterial and venous thrombosis1. This evidence concerns the gene JAK2 and acquired polycythemia vera.